DOCSLIB.ORG

Mirna Expression Changes in Arsenic-Induced Skin Cancer in Vitro and in Vivo

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mirna Expression Changes in Arsenic-Induced Skin Cancer in Vitro and in Vivo University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 8-2017 MiRNA expression changes in arsenic-induced skin cancer in vitro and in vivo. Laila Al-Eryani University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Part of the Medicine and Health Sciences Commons Recommended Citation Al-Eryani, Laila, "MiRNA expression changes in arsenic-induced skin cancer in vitro and in vivo." (2017). Electronic Theses and Dissertations. Paper 2767. https://doi.org/10.18297/etd/2767 This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. MIRNA EXPRESSION CHANGES IN ARSENIC-INDUCED SKIN CANCER IN VITRO AND IN VIVO By Laila Al-Eryani A Dissertation Submitted To The Faculty of the School Of Medicine of the University Of Louisville In Partial Fulfillment of the Requirements For The Degree Of Doctor of Philosophy in Pharmacology and Toxicology Department Of Pharmacology and Toxicology University Of Louisville Louisville, Kentucky August 2017 MIRNA EXPRESSION CHANGES IN ARSENIC-INDUCED SKIN CANCER IN VITRO AND IN VIVO By Laila Al-Eryani Dissertation approved on August 03, 2017 By the following Dissertation Committee: J. Christopher States, Ph.D. Carolyn M. Klinge Ph.D. Shesh N. Rai, Ph.D. Chendil Damodaran, Ph.D. Theodore Kalbfleisch, Ph.D. ii ACKNOWLEDGMENTS I would like to express my deepest gratitude to my mentor Dr. J. Christopher States for his persistent help, guidance, motivation, patience and very big and kind heart through my Ph.D. journey. I want also to thank my committee members for their guidance, support and assistance starting form Dr. Damodaran and his lab members and Dr. Tyagi and Dr. Pal for all their technical help. I would also like to thank Dr. Shesh Rai and Dr. Pan for running the statistical analyses. I want also to thank Dr. Kalbfleisch for his help with the NGS data and Dr. Klinge for her advice and helping with troubleshooting. I also sincerely thank the DNA Core manager at the University of Louisville, Sabine Waigel, for all the tremendous help with hybridization microarray analyses and other analyses and being always welcoming and welling to help. Special thank you goes to Vennila Arumugam for all the technical support. My gratitude also goes to members of the Price Institute of Surgery at the University of Louisville, in particular Dr. Galandiuk, M. Robert Eichenberger, Dr. Chien, Dr. Sarojini for the access to instruments and enormous technical help for the LCM and skin lesions study. I would like to thank Dr. Malone for her tremendous help for diagnosing the skin lesions. I sincerely thank Dr. Jala for his technical help with the cell cycle assays and Josiah Hardesty for his technical help with western blot troubleshooting. iii I want also to thank Vanessa States for running the skin lesions preliminary miRNA expression data and Gregory States for designing the program used to facilitate measuring the cells migration. I wish also to thank all the summer students who contributed to the project, Sam Jenkins, who helped tremendously with the LCM, and Jana Peremarti. I also sincerely thank the Fulbright program for giving me the chance to pursue my graduate studies. Without their initial support during my master, I would have been able to pursue my Ph.D. Many thanks to the Integrated Program in Biomedical Sciences (IPIBS) and the department of Pharmacology and Toxicology for supporting me throughout my Ph.D. Last but not least I am very thankful to my amazing family, mom, dad and lamia along with my friends Banrida, Sabrin, Safa, Heather, Linda and Holly for all their continuous support which without I would never be where I am now. This work was supported in part by NIH grants R21ES023627, R01ES011314, T35ES014559, R25CA134283, and a Competitive Enhancement Grant from the University of Louisville Office of the Executive Vice President for Research and Innovation. Finally, I dedicate this dissertation to the memory of a beautiful soul and a very special person that left us too soon, my bother, Luai Al-Eryani. I will always love you, remember you and cherished you and every moment we spent together, you are deeply missed! iv ABSTRACT MIRNA EXPRESSION CHANGES IN ARSENIC-INDUCED SKIN CANCER IN VITRO AND IN VIVO Laila Al-Eryani August 03, 2017 Arsenic is a naturally prevalent metalloid. Chronic arsenic ingestion through drinking water causes skin cancer. Arsenic-induced cancer mechanisms are not well defined. Epigenetic changes, including microRNA expression changes, might be playing a role. This dissertation investigates the impact of miRNA expression changes in arsenic-induced skin cancer. MiRNA expression was measure and compared using 3 different techniques, RTq-PCR, hybridization arrays and RNA-sequencing. MiRNAs differential expression in skin lesions was phenotype- and stage-related. Immortalized human keratinocytes (HaCaT) were transformed by chronic low arsenite exposure serving as a model for arsenic-induced skin carcinogenesis. Early changes in miRNAs and target mRNAs contribute to arsenic-induced carcinogenesis. Throughout the time course of arsenic exposure, dysregulation of cells’ growth and cancer-related pathways were identified. Comparisons between the miRNA profiles in lesions and cells predict some miRNAs may serve as biomarkers and/or therapeutic targets for arsenic-induced tumors. This dissertation provides strong evidences of epigenetic changes related to carcinogenesis in arsenic-induced skin cancer. v TABLE OF CONTENTS Acknowledgements.…………………………………………………...………….. iii Abstract………………………...……………………………………………….… v List of Tables……………..…………………………………………………….… viii List of Figures…………………………………………………………….……… ix Chapter 1: General Introduction……………………………………………… 1 Chapter 2: MiRNA Expression Profiles of Premalignant and Malignant Arsenic-Induced Skin Lesions Introduction…………………………………………………….….. 13 . Materials and Methods…………………………………………… 19 Results…………………………………………………….……….. 21 Discussion.…………………………………………………….…... 33 Chapter 3: Differentially Expressed MiRNAs and MRNAs at Early Stages of Transformation of HaCaT Cells Chronically Exposed to Low Arsenite Introduction…………………………………………………….….. 40 Materials and Methods…………………………………………… 43 Results…………………………………………………….……….. 47 Discussion………….……………………………………………… 61 Chapter 4: Cell Cycle Pathway Dysregulation in Human Keratinocytes at Early Stages of Chronic Exposure to Low Arsenite Introduction…………………………………………………….….. 68 Materials and Methods…………………………………………… 70 Results…………………………………………………….……….. 73 Discussion………….……………………………………………… 78 vi Chapter 5: A Longitudinal Study on Small RNA And MRNA Expression Profiles in The Chronic Exposure HaCaT Model Introduction…………………………………………………….….. 80 Materials and Methods…………………………………………… 83 Results…………………………………………………….……….. 87 Discussion………….……………………………………………… 109 Chapter 6: MiRNA Expression Profiles Comparisons Across Three Different Techniques Introduction…………………………………………………….….. 112 Materials and Methods…………………………………………… 114 Results…………………………………………………….……….. 116 Discussion………….……………………………………………… 126 Chapter 7: Overall Discussion, Conclusions and Future Directions .……. 129 References……………………………………...…………………………….….. 135 Appendix: List of Abbreviations……………………………………………… 171 Curriculum Vitae……………………………………………...………………….. 174 vii LIST OF TABLES Table 2.1. Demographics of study population 22 Table 2.2. Differentially expressed miRNAs in Arsenic-induced 27 Skin Lesions and Their Expression Table 3.1. Differentially expressed small RNAs at both 3 and 7 52 weeks of exposure to arsenite Table 3.2. Top 10 pathways of the differentially expressed 38 54 mRNAs at both 3 and 7 weeks that are predicted targets of miRNAs differentially expressed at both 3 and 7 weeks Table 4.1. Pathways populated by differentially expressed mRNAs 75 7 weeks Table 5.1. MiRNAs differentially expressed at more than one time 88 point Table 5.2. Pathway analysis of differentially expressed genes at 7, 90 19 and 28 weeks Table 5.3. Pathway analysis of differentially expressed mRNAs 104 targets of differentially expressed miRNAs Table 6.1. Differentially expressed miRNAs at 3 weeks of 117 chronically arsenic- exposed/unexposed HaCaT cells using RT-qPCR array cards Table 6.2. Differentially expressed miRNAs at 3 weeks in exposed 119 cells vs. unexposed cells to those of unexposed cell vs. skin lesions Table 6.3. Differentially expressed miRNAs at 3 weeks of 121 chronically arsenic-exposed HaCaT cells in both hybridization microarrays and RT-qPCR array cards Table 6.4. Differentially expressed miRNAs at 7 weeks of 123 chronically arsenic-exposed HaCaT cells in both hybridization microarrays and Next-Generation Sequencing (NGS) Table 6.5. MiRNAs differentially expressed in chronically arsenic- 125 exposed HaCaT cells and arsenic-induced skin lesions viii LIST OF FIGURES Figure 1.1. miRNA biogenesis 6 Figure 2.1. Skin Cancer Progression 16 Figure 2.2. Arsenic induced premalignant and malignant skin 24 lesions Figure 2.3. Differentially expressed miRNA in Arsenic-induced 26 Skin Lesions Figure 3.1. Impact of arsenite exposure on cumulative HaCaT 48 cell population
Load more

Recommended publications
  • Mirnas Generated from Meg3-Mirg Locus Are Downregulated During Aging
    www.aging-us.com AGING 2021, Vol. 13, No. 12 Research Paper miRNAs generated from Meg3-Mirg locus are downregulated during aging Ana-Mihaela Lupan1,*, Evelyn-Gabriela Rusu1,*, Mihai Bogdan Preda1, Catalina Iolanda Marinescu1, Cristina Ivan2, Alexandrina Burlacu1 1Laboratory of Stem Cell Biology, Institute of Cellular Biology and Pathology “Nicolae Simionescu”, Bucharest 050568, Romania 2Department of Experimental Therapeutics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA *Equal contribution Correspondence to: Alexandrina Burlacu; email: [email protected] Keywords: aging, miRNA, Meg3-Mirg locus, cardiac fibroblasts, heart ventricles Received: October 31, 2020 Accepted: June 2, 2021 Published: June 22, 2021 Copyright: © 2021 Lupan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Aging determines a multilevel functional decline and increases the risk for cardiovascular pathologies. MicroRNAs are recognized as fine tuners of all cellular functions, being involved in various cardiac diseases. The heart is one of the most affected organs in aged individuals, however little is known about the extent and robustness to which miRNA profiles are modulated in cardiac cells during aging. This paper provides a comprehensive characterization of the aging-associated miRNA profile in the murine cardiac fibroblasts, which are increasingly recognized for their active involvement in the cardiac physiology and pathology. Next- generation sequencing of cardiac fibroblasts isolated from young and old mice revealed that an important fraction of the miRNAs generated by the Meg3-Mirg locus was downregulated during aging.
    [Show full text]
  • Lysophosphatidic Acid Signaling in the Nervous System
    Neuron Review Lysophosphatidic Acid Signaling in the Nervous System Yun C. Yung,1,3 Nicole C. Stoddard,1,2,3 Hope Mirendil,1 and Jerold Chun1,* 1Molecular and Cellular Neuroscience Department, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA 92037, USA 2Biomedical Sciences Graduate Program, University of California, San Diego School of Medicine, La Jolla, CA 92037, USA 3Co-first author *Correspondence: [email protected] http://dx.doi.org/10.1016/j.neuron.2015.01.009 The brain is composed of many lipids with varied forms that serve not only as structural components but also as essential signaling molecules. Lysophosphatidic acid (LPA) is an important bioactive lipid species that is part of the lysophospholipid (LP) family. LPA is primarily derived from membrane phospholipids and signals through six cognate G protein-coupled receptors (GPCRs), LPA1-6. These receptors are expressed on most cell types within central and peripheral nervous tissues and have been functionally linked to many neural pro- cesses and pathways. This Review covers a current understanding of LPA signaling in the nervous system, with particular focus on the relevance of LPA to both physiological and diseased states. Introduction LPA synthesis/degradative enzymes (reviewed in Sigal et al., The human brain is composed of approximately 60%–70% lipids 2005; Brindley and Pilquil, 2009; Perrakis and Moolenaar, by dry weight (Svennerholm et al., 1994). These lipids can be 2014). In view of the broad neurobiological influences of LPA divided into two major pools, structural and signaling, which signaling, its dysregulation may lead to diverse neuropathologies include well-known families such as cholesterol, fatty acids, ei- (Bandoh et al., 2000; Houben and Moolenaar, 2011; Yung et al., cosanoids, endocannabinoids, and prostaglandins (Figure 1).
    [Show full text]
  • Figure S1. Representative Report Generated by the Ion Torrent System Server for Each of the KCC71 Panel Analysis and Pcafusion Analysis
    Figure S1. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. A Figure S1. Continued. Representative report generated by the Ion Torrent system server for each of the KCC71 panel analysis and PCaFusion analysis. (A) Details of the run summary report followed by the alignment summary report for the KCC71 panel analysis sequencing. (B) Details of the run summary report for the PCaFusion panel analysis. B Figure S2. Comparative analysis of the variant frequency found by the KCC71 panel and calculated from publicly available cBioPortal datasets. For each of the 71 genes in the KCC71 panel, the frequency of variants was calculated as the variant number found in the examined cases. Datasets marked with different colors and sample numbers of prostate cancer are presented in the upper right. *Significantly high in the present study. Figure S3. Seven subnetworks extracted from each of seven public prostate cancer gene networks in TCNG (Table SVI). Blue dots represent genes that include initial seed genes (parent nodes), and parent‑child and child‑grandchild genes in the network. Graphical representation of node‑to‑node associations and subnetwork structures that differed among and were unique to each of the seven subnetworks. TCNG, The Cancer Network Galaxy. Figure S4. REVIGO tree map showing the predicted biological processes of prostate cancer in the Japanese. Each rectangle represents a biological function in terms of a Gene Ontology (GO) term, with the size adjusted to represent the P‑value of the GO term in the underlying GO term database.
    [Show full text]
  • Screening Differentially Expressed Genes of Pancreatic Cancer Between Mongolian and Han People Using Bioinformatics Technology
    Screening differentially expressed genes of pancreatic cancer between Mongolian and Han people using bioinformatics technology Jiasheng Xu First Aliated Hospital of Nanchang University Kaili Liao Second Aliated Hospital of Nanchang University ZHONGHUA FU First Aliated Hospital of Nanchang University ZHENFANG XIONG ( [email protected] ) The First Aliated Hospital of Nanchang University https://orcid.org/0000-0003-2062-9204 Research article Keywords: Pancreatic ductal cell carcinoma; Affymetrix gene expression prole; Gene differential expression; GO analysis; Pathway analysis; Mongolian Posted Date: October 14th, 2019 DOI: https://doi.org/10.21203/rs.2.11118/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published at BMC Cancer on April 9th, 2020. See the published version at https://doi.org/10.1186/s12885-020-06722-7. Page 1/19 Abstract Objective: To screen and analyze differentially expressed genes in pancreatic carcinoma tissues taken from Mongolian and Han patients by Affymetrix Genechip. Methods: Pancreatic ductal cell carcinoma tissues were collected from the Mongolian and Han patients undergoing resection in the Second Aliated Hospital of Nanchang University from March 2015 to May 2018 and the total RNA was extracted. Differentially expressed genes were selected from the total RNA qualied by Nanodrop 2000 and Agilent 2100 using Affymetrix and a cartogram was drawn; The gene ontology (GO) analysis and Pathway analysis were used for the collection and analysis of biological information of these differentially expressed genes. Finally, some differentially expressed genes were veried by real-time PCR. Results: Through the microarray analysis of gene expression, 970 differentially expressed genes were detected by comparing pancreatic cancer tissue samples between Mongolian and Han patients.
    [Show full text]
  • The Identification of Proteins That Interact with the N-Terminal Domain of Pitx2c
    The identification of proteins that interact with the N-terminal domain of Pitx2c Dora Siontas A thesis submitted to McGill University in partial fulfillment of the requirement of the degree of Master of Science Department of Experimental Medicine McGill University Montreal, Quebec Canada August, 2011 © Dora Siontas Table of Contents Page ABSTRACT……………………………………………………………………..… i RÉSUMÉ………………….…………………………………………………...….. ii ACKNOWLEDGMENTS……………….……………………...…………...…... iii ABBREVIATIONS……………………...……………………………………..… iv LIST OF FIGURES ………………………………………………………..…... viii LIST OF TABLES……………………..……………………………………......... x 1. INTRODUCTION…………………………………………………………….... 1 1.1 Left-right asymmetric patterning……………………………………...…. 1 1.2 The left-right asymmetric molecular cascade………………………..…... 2 1.2.1 The left-right molecular cascade in the chick embryo..……………. 2 1.2.2 The left-right molecular cascade in the mouse embryo……….…… 7 1.3 The Pitx2 gene and protein isoforms………………………………….… 10 1.3.1 Identification of PITX2 as a mutated gene in ARS…………......… 11 1.3.2 Pitx2 function….……………………………..………………........… 11 1.3.3 Pitx2 isoforms…………………………………………..………..….. 13 1.3.4 Expression patterns of the different Pitx2 isoforms………............. 15 1.3.5 Pitx2 is important for asymmetric morphogenesis………………... 17 1.4 The Pitx2c N-terminal domain………………………………………...… 19 1.4.1 The Pitx2c N-terminal domain………………………………..…..… 19 1.4.2 Functional experiments with the Pitx2c N-terminal domain….….. 20 1.4.3 Pitx2-interacting proteins…………….……………………………... 23 2. HYPOTHESIS AND OBJECTIVES……………………………………..….. 25 2.1 Rationale…………………………………………………………………. 25 2.2 Hypothesis…………………………………………………………......… 25 2.3 Objectives……………………………………………………….……….. 26 3. MATERIALS AND METHODS………………………………………….…… 27 3.1 Cloning of the m2cN into pGBKT7………………………………………. 27 3.1.1 Midipreparation of pGBKT7…………………………………...…… 27 3.1.2 RT-PCR of m2cN cDNA…………………………………………..…. 27 3.1.3 Purification and digestion of the m2cN and the pGBKT7 vector….
    [Show full text]
  • An in Cellulo-Derived Structure of PAK4 in Complex with Its Inhibitor Inka1
    ARTICLE Received 27 May 2015 | Accepted 21 Sep 2015 | Published 26 Nov 2015 DOI: 10.1038/ncomms9681 OPEN An in cellulo-derived structure of PAK4 in complex with its inhibitor Inka1 Yohendran Baskaran1,*, Khay C. Ang1,2,*, Praju V. Anekal1, Wee L. Chan1, Jonathan M. Grimes3,4, Ed Manser1,5,6 & Robert C. Robinson1,2 PAK4 is a metazoan-specific kinase acting downstream of Cdc42. Here we describe the structure of human PAK4 in complex with Inka1, a potent endogenous kinase inhibitor. Using single mammalian cells containing crystals 50 mm in length, we have determined the in cellulo crystal structure at 2.95 Å resolution, which reveals the details of how the PAK4 catalytic domain binds cellular ATP and the Inka1 inhibitor. The crystal lattice consists only of PAK4– PAK4 contacts, which form a hexagonal array with channels of 80 Å in diameter that run the length of the crystal. The crystal accommodates a variety of other proteins when fused to the kinase inhibitor. Inka1–GFP was used to monitor the process crystal formation in living cells. Similar derivatives of Inka1 will allow us to study the effects of PAK4 inhibition in cells and model organisms, to allow better validation of therapeutic agents targeting PAK4. 1 Institute of Molecular and Cell Biology, A*STAR (Agency for Science, Technology and Research), Biopolis, Proteos Building, 61 Biopolis Drive, 8-15, Singapore 138673, Singapore. 2 Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore. 3 Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • G Protein-Coupled Receptors
    G PROTEIN-COUPLED RECEPTORS Overview:- The completion of the Human Genome Project allowed the identification of a large family of proteins with a common motif of seven groups of 20-24 hydrophobic amino acids arranged as α-helices. Approximately 800 of these seven transmembrane (7TM) receptors have been identified of which over 300 are non-olfactory receptors (see Frederikson et al., 2003; Lagerstrom and Schioth, 2008). Subdivision on the basis of sequence homology allows the definition of rhodopsin, secretin, adhesion, glutamate and Frizzled receptor families. NC-IUPHAR recognizes Classes A, B, and C, which equate to the rhodopsin, secretin, and glutamate receptor families. The nomenclature of 7TM receptors is commonly used interchangeably with G protein-coupled receptors (GPCR), although the former nomenclature recognises signalling of 7TM receptors through pathways not involving G proteins. For example, adiponectin and membrane progestin receptors have some sequence homology to 7TM receptors but signal independently of G-proteins and appear to reside in membranes in an inverted fashion compared to conventional GPCR. Additionally, the NPR-C natriuretic peptide receptor has a single transmembrane domain structure, but appears to couple to G proteins to generate cellular responses. The 300+ non-olfactory GPCR are the targets for the majority of drugs in clinical usage (Overington et al., 2006), although only a minority of these receptors are exploited therapeutically. Signalling through GPCR is enacted by the activation of heterotrimeric GTP-binding proteins (G proteins), made up of α, β and γ subunits, where the α and βγ subunits are responsible for signalling. The α subunit (tabulated below) allows definition of one series of signalling cascades and allows grouping of GPCRs to suggest common cellular, tissue and behavioural responses.
    [Show full text]
  • Phospho-PAK4 (Ser474)/PAK5 (Ser602)/PAK6 (Ser560) Antibody Detects Endogenous 12
    Revision 1 C 0 2 - t Phospho-PAK4 (Ser474)/PAK5 a e r o t (Ser602)/PAK6 (Ser560) Antibody S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 1 4 Web: [email protected] 2 www.cellsignal.com 3 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB H M GP Endogenous 72 (PAK4). 82 Rabbit Q9NQU5, Q9P286, O96013 56924, 57144, 10298 (PAK6). 90 (PAK5). p y g y p y Product Usage Information pivotal role in regulating the activity and function of PAK4 (10). PAK family members are widely expressed, and often overexpressed in human cancer (11,12). Application Dilution 1. Knaus, U.G. and Bokoch, G.M. (1998) Int. J. Biochem. Cell Biol. 30, 857-62. 2. Daniels, R.H. et al. (1998) EMBO J. 17, 754-64. Western Blotting 1:1000 3. King, C.C. et al. (2000) J. Biol. Chem. 275, 41201-9. 4. Manser, E. et al. (1997) Mol. Cell. Biol. 17, 1129-43. Storage 5. Gatti, A. et al. (1999) J. Biol. Chem. 274, 8022-8. 6. Lei, M. et al. (2000) Cell 102, 387-97. Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% 7. Chong, C. et al. (2001) J. Biol. Chem. 276, 17347-53. glycerol. Store at –20°C. Do not aliquot the antibody. 8. Zhao, Z. et al. (2000) Mol. Cell. Biol. 20, 3906-17. 9.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Screening of Potential Genes and Transcription Factors Of
    ANIMAL STUDY e-ISSN 1643-3750 © Med Sci Monit, 2018; 24: 503-510 DOI: 10.12659/MSM.907445 Received: 2017.10.08 Accepted: 2018.01.01 Screening of Potential Genes and Transcription Published: 2018.01.25 Factors of Postoperative Cognitive Dysfunction via Bioinformatics Methods Authors’ Contribution: ABE 1 Yafeng Wang 1 Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical Study Design A AB 1 Ailan Huang University, Nanning, Guangxi, P.R. China Data Collection B 2 Department of Gynecology, People’s Hospital of Guangxi Zhuang Autonomous Statistical Analysis C BEF 1 Lixia Gan Region, The First Affiliated Hospital of Guangxi Medical University, Nanning, Data Interpretation D BCF 1 Yanli Bao Guangxi, P.R. China Manuscript Preparation E BDF 1 Weilin Zhu 3 Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical Literature Search F University, Nanning, Guangxi, P.R. China Funds Collection G EF 1 Yanyan Hu AE 1 Li Ma CF 2 Shiyang Wei DE 3 Yuyan Lan Corresponding Author: Yafeng Wang, e-mail: [email protected] Source of support: Departmental sources Background: The aim of this study was to explore the potential genes and transcription factors involved in postoperative cognitive dysfunction (POCD) via bioinformatics analysis. Material/Methods: GSE95070 miRNA expression profiles were downloaded from Gene Expression Omnibus database, which in- cluded five hippocampal tissues from POCD mice and controls. Moreover, the differentially expressed miRNAs (DEMs) between the two groups were identified. In addition, the target genes of DEMs were predicted using Targetscan 7.1, followed by protein-protein interaction (PPI) network construction, functional enrichment anal- ysis, pathway analysis, and prediction of transcription factors (TFs) targeting the potential targets.
    [Show full text]
  • Transcriptome Analysis of Human Diabetic Kidney Disease
    ORIGINAL ARTICLE Transcriptome Analysis of Human Diabetic Kidney Disease Karolina I. Woroniecka,1 Ae Seo Deok Park,1 Davoud Mohtat,2 David B. Thomas,3 James M. Pullman,4 and Katalin Susztak1,5 OBJECTIVE—Diabetic kidney disease (DKD) is the single cases, mild and then moderate mesangial expansion can be leading cause of kidney failure in the U.S., for which a cure has observed. In general, diabetic kidney disease (DKD) is not yet been found. The aim of our study was to provide an considered a nonimmune-mediated degenerative disease unbiased catalog of gene-expression changes in human diabetic of the glomerulus; however, it has long been noted that kidney biopsy samples. complement and immunoglobulins sometimes can be de- — tected in diseased glomeruli, although their role and sig- RESEARCH DESIGN AND METHODS Affymetrix expression fi arrays were used to identify differentially regulated transcripts in ni cance is not clear (4). 44 microdissected human kidney samples. The DKD samples were The understanding of DKD has been challenged by multi- significant for their racial diversity and decreased glomerular ple issues. First, the diagnosis of DKD usually is made using filtration rate (~20–30 mL/min). Stringent statistical analysis, using clinical criteria, and kidney biopsy often is not performed. the Benjamini-Hochberg corrected two-tailed t test, was used to According to current clinical practice, the development of identify differentially expressed transcripts in control and diseased albuminuria in patients with diabetes is sufficient to make the glomeruli and tubuli. Two different Web-based algorithms were fi diagnosis of DKD (5). We do not understand the correlation used to de ne differentially regulated pathways.
    [Show full text]